These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23334072)

  • 21. Advances in epilepsy treatment: lacosamide pharmacokinetic profile.
    Cawello W; Stockis A; Andreas JO; Dimova S
    Ann N Y Acad Sci; 2014 Nov; 1329():18-32. PubMed ID: 25167889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United Kingdom (UK).
    Flores L; Kemp S; Colbeck K; Moran N; Quirk J; Ramkolea P; von Oertzen TJ; Nashef L; Richardson MP; Goulding P; Elwes R
    Seizure; 2012 Sep; 21(7):512-7. PubMed ID: 22698379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lacosamide as adjunctive therapy in treatment-resistant epilepsy in childhood.
    Gulati P; Cannell P; Ghia T; Bint L; Walsh P; Ghosh S; Nagarajan L
    J Paediatr Child Health; 2015 Aug; 51(8):794-7. PubMed ID: 25683595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy.
    Stöhr T; Kupferberg HJ; Stables JP; Choi D; Harris RH; Kohn H; Walton N; White HS
    Epilepsy Res; 2007 May; 74(2-3):147-54. PubMed ID: 17433624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs.
    Contin M; Albani F; Riva R; Candela C; Mohamed S; Baruzzi A
    Ther Drug Monit; 2013 Dec; 35(6):849-52. PubMed ID: 23942540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lacosamide in patients with pharmacoresistant epilepsy.
    Verrotti A; Loiacono G; Olivieri C; Zulli E; Zaccara G
    Expert Opin Pharmacother; 2012 Oct; 13(14):2065-72. PubMed ID: 22873760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation.
    Giráldez BG; Toledano R; García-Morales I; Gil-Nagel A; López-González FJ; Tortosa D; Ojeda J; Serratosa JM
    Seizure; 2015 Jul; 29():119-22. PubMed ID: 26076854
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.
    Harris JA; Murphy JA
    Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sinus node dysfunction: an adverse effect of lacosamide.
    Chinnasami S; Rathore C; Duncan JS
    Epilepsia; 2013 Jun; 54(6):e90-3. PubMed ID: 23360388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
    Patsalos PN; Berry DJ
    Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose, and concomitant antiepileptic drugs.
    Markoula S; Teotonio R; Ratnaraj N; Duncan JS; Sander JW; Patsalos PN
    Ther Drug Monit; 2014 Aug; 36(4):494-8. PubMed ID: 24562047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forced normalization and psychosis following use of lacosamide.
    Abou Khaled K; Khoury J; Macaron G; Richa S
    Seizure; 2016 Oct; 41():96-9. PubMed ID: 27522575
    [No Abstract]   [Full Text] [Related]  

  • 33. Adjunctive lacosamide in clinical practice: sodium blockade with a difference?
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term retention of lacosamide in a large cohort of people with medically refractory epilepsy: a single centre evaluation.
    Novy J; Bartolini E; Bell GS; Duncan JS; Sander JW
    Epilepsy Res; 2013 Sep; 106(1-2):250-6. PubMed ID: 23796862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus.
    Koubeissi MZ; Mayor CL; Estephan B; Rashid S; Azar NJ
    Acta Neurol Scand; 2011 Feb; 123(2):142-6. PubMed ID: 21198444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre.
    Kamel JT; DeGruyter MA; D'Souza WJ; Cook MJ
    Acta Neurol Scand; 2013 Mar; 127(3):149-53. PubMed ID: 22845761
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjunctive lacosamide--5 years' clinical experience.
    Stephen LJ; Kelly K; Parker P; Brodie MJ
    Epilepsy Res; 2014 Oct; 108(8):1385-91. PubMed ID: 25064538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide.
    Tilz C; Resch R; Hofer T; Eggers C
    Epilepsia; 2010 Feb; 51(2):316-7. PubMed ID: 19674050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures.
    García-Morales I; Delgado RT; Falip M; Campos D; García ME; Gil-Nagel A
    Seizure; 2011 Dec; 20(10):801-4. PubMed ID: 21917484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lacosamide for the treatment of epilepsy.
    de Biase S; Gigli GL; Valente M; Merlino G
    Expert Opin Drug Metab Toxicol; 2014 Mar; 10(3):459-68. PubMed ID: 24479852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.